{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:18:38Z","timestamp":1761513518686,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.clbc.2016.05.005","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T21:02:50Z","timestamp":1463259770000},"page":"364-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase 2 Study of Trabectedin in Patients With Hormone Receptor\u2013Positive, HER-2\u2013Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene"],"prefix":"10.1016","volume":"16","author":[{"given":"Ahmad","family":"Awada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mafalda","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"L\u00f3pez-Tarruella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Espie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Lardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Extremera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva M.","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2016.05.005_bib1","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2016.05.005_bib2","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer statistics. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/breast.html. Accessed: November 15, 2015."},{"key":"10.1016\/j.clbc.2016.05.005_bib3","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/91008","article-title":"Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair","volume":"7","author":"Takebayashi","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.clbc.2016.05.005_bib4","doi-asserted-by":"crossref","first-page":"8155","DOI":"10.1158\/0008-5472.CAN-06-0179","article-title":"Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin","volume":"66","author":"Herrero","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2016.05.005_bib5","doi-asserted-by":"crossref","first-page":"13062","DOI":"10.1073\/pnas.0609877104","article-title":"Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743","volume":"104","author":"Soares","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2016.05.005_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ejca.2008.01.003","article-title":"Role of homologous recombination in trabectedin-induced DNA damage","volume":"44","author":"Tavecchio","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2016.05.005_bib7","first-page":"S26","article-title":"Antiproliferative activity and mode of action of novel compounds of marine origin","volume":"310","author":"D'Incalci","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2016.05.005_bib8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1158\/1535-7163.MCT-07-2432","article-title":"Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin","volume":"7","author":"Casado","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clbc.2016.05.005_bib9","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ejca.2008.11.019","article-title":"Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer","volume":"45","author":"Sessa","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2016.05.005_bib10","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.bjc.6603142","article-title":"A\u00a0phase II study of Yondelis\u00ae (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer","volume":"94","author":"Zelek","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2016.05.005_bib11","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.clbc.2014.06.006","article-title":"Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens","volume":"14","author":"Goldstein","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2016.05.005_bib12","doi-asserted-by":"crossref","unstructured":"Tedesco KL, Blum JL, Gon\u00e7alves A, et\u00a0al. Final results of a phase II trial of trabectedin (T) in triple negative, HER2 positive and BRCA1\/2 germ-line\u2013mutated metastatic breast cancer (MBC) patients [abstract 1125]. Paper presented at: American Society of Clinical Oncology 47th annual meeting; June 3-7, 2011; Chicago, IL.","DOI":"10.1200\/jco.2011.29.15_suppl.1125"},{"key":"10.1016\/j.clbc.2016.05.005_bib13","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdu134","article-title":"Activity of trabectedin in germline BRCA1\/2-mutated metastatic breast cancer: results of an international first-in-class phase II study","volume":"25","author":"Delaloge","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2016.05.005_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2016.05.005_bib15","unstructured":"National Cancer Institute Common Terminology Criteria for the Classification of Adverse Events, version 4.0. Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed: November 15, 2015."},{"key":"10.1016\/j.clbc.2016.05.005_bib16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s10637-011-9662-0","article-title":"A\u00a0retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials","volume":"30","author":"Le Cesne","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clbc.2016.05.005_bib17","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00280-012-1864-4","article-title":"A\u00a0comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin","volume":"69","author":"Grosso","year":"2012","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091630101X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091630101X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:14:57Z","timestamp":1761513297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682091630101X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S152682091630101X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2016.05.005","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Study of Trabectedin in Patients With Hormone Receptor\u2013Positive, HER-2\u2013Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2016.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}